Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$8.89M | -$23.0M | -$53.2M | -$81.4M | -$74.6M | -$114M |
| Net income | -$9.61M | -$23.0M | -$51.5M | -$75.5M | -$69.6M | -$127M |
| EPS (diluted) | -$40.31 | -$1.87 | -$2.10 | -$2.87 | -$2.44 | -$3.19 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.86M | -$27.4M | -$39.1M | -$56.8M | -$71.2M | -$94.7M |
| Capital expenditures | — | $181K | $195K | $142K | — | $196K |
| Free cash flow | — | -$27.6M | -$39.3M | -$56.9M | — | -$94.9M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.57M | $54.2M | $22.4M | $23.5M | $69.4M | $88.4M |
| Total assets | $4.71M | $175M | $135M | $127M | $72.8M | $350M |
| Total liabilities | $1.77M | $2.94M | $8.56M | $18.0M | $120M | $17.3M |
| Shareholders' equity | -$13.3M | $172M | $127M | $109M | $1.00K | $333M |
| Retained earnings | -$13.4M | -$36.4M | -$87.9M | -$163M | -$47.0M | -$174M |
| Shares (wtd avg diluted) | 243K | 12.3M | 24.5M | 26.3M | 28.6M | 31.4M |
Every figure is extracted from Jade Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.